The Top 100 Drugs

The Top 100 Drugs Clinical Pharmacology and Practical PrescribingEdition 2

Editors: By Andrew Hitchings, BSc(Hons) MBBS PhD MRCP FHEA FFICM, Dagan Lonsdale, BSc(Hons) MBBS MRCP FHEA, Daniel Burrage, BSc(Hons) MBBS MSc (Med Ed) MRCP FHEA and Emma Baker, MBChB PhD FRCP FBPhS
ISBN: 9780702074424
Publication Date : Nov 27, 2018
Page Count: 314
Retail Price:
  • EUR: €19.99

To allow you to review the book immediately, we would like to supply the digital version where possible. If you prefer to request the print book or only print is available, please allow 10-14 days for delivery.

  • Description
  • About the Editor
Description

Now in its second edition, this highly successful guide to safe prescribing of the most common classes of drugs is your starting point for safe and effective practice.

The first edition was a direct response to requests from students for a compendium of the 100 most important drugs in the NHS. Research led by Professor Emma Baker identified the ‘top 100 drugs’ by their importance and prescribing frequency.

Key Features

  • The top 100 drugs and the five most important intravenous fluids are presented using a clear, consistent layout across double-page spreads.
  • Drugs are arranged alphabetically and also listed by organ system and clinical indication, providing multiple pathways into the information.
  • Clinical pharmacology is discussed under the headings: common indications; mechanisms of action; important adverse effects; warnings; and important interactions.
  • Practical prescribing is discussed under the headings: prescription; administration; communication; monitoring; and cost.
  • A clinical tip is presented for every drug.
  • Single-best-answer questions are provided for self-assessment and to show how information from several drugs may be integrated.

New Features

  • Double the number of self-assessment questions, from 50 to 100.
  • 11 new drugs added and 11 dropped according the re-run research into the top 100 drugs in current use.
About the Editor
By Andrew Hitchings, BSc(Hons) MBBS PhD MRCP FHEA FFICM, Senior Lecturer in Clinical Pharmacology, St George’s, University of London; Honorary Consultant in Neurointensive Care, St George’s University Hospitals NHS Foundation Trust, London, UK ; Dagan Lonsdale, BSc(Hons) MBBS MRCP FHEA, Honorary Senior Lecturer, St George’s, University of London; Specialty Registrar in Clinical Pharmacology, General Medicine and Intensive Care Medicine, St George’s University Hospitals NHS Foundation Trust, London, UK ; Daniel Burrage, BSc(Hons) MBBS MSc (Med Ed) MRCP FHEA , NIHR Doctoral Research Fellow, St George’s, University of London; Specialty Registrar in Clinical Pharmacology, General Medicine and Stroke Medicine, St George’s University Hospitals NHS Foundation Trust, London, UK and Emma Baker, MBChB PhD FRCP FBPhS, Professor of Clinical Pharmacology, Biomedical Sciences, St George’s University of London; Honorary Consultant Physician, St George’s University Hospitals NHS Foundation Trust, London, UK.